PhRMA Report Shows New Vaccine Development - - BioPharm International

ADVERTISEMENT

PhRMA Report Shows New Vaccine Development



A landmark report on hundreds of new vaccines in development from the Pharmaceutical Research and Manufacturers of America (PhRMA) reflects robust R&D in this field. Biopharmaceutical companies are developing 271 vaccines, about half of them to prevent infectious diseases, and smaller numbers targeted at allergies, neurological disorders, and other conditions, according to the report. A big-growth area is in therapeutic vaccines to treat cancer by boosting the body’s immune response to halt tumor growth, as with test vaccines to treat metastatic renal cell cancer and melanoma. Other new vaccines in development aim to combat a common form of genital herpes, and reports from Africa cite huge drops meningitis cases following introduction of the MenAfriVac therapy in 2010. Similarly, broader use of vaccines against HPV (human papillomavirus) has greatly cut US infection rates in teenage girls.

More vaccine development means expansion of manufacturing capability. Merck continues to expand and upgrade vaccine production despite major corporate cutbacks, as seen in recent FDA approval a plant in Durham, NC to manufacture bulk varicella for vaccines against chicken pox and shingles.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

PDA Announces Technical Report on Drug Shortages
September 9, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
DPT Laboratories Acquires Media Pharmaceuticals' Lakewood Facilities
September 5, 2014
Merck KGaA Breaks Ground on Facility in China
September 5, 2014
FDA Releases Guidance Electronic Submission of Lot Distribution Reports
September 5, 2014
Author Guidelines

Click here